Please ensure Javascript is enabled for purposes of website accessibility

Buying Cybin Stock Right Now Could Be a Brilliant Move

By Alex Carchidi – Sep 2, 2021 at 6:19AM

Key Points

  • Buying undiscovered gems is a great way to get exposure to upside.
  • Psychedelic medicines are highly promising treatments for mental illnesses, but they're nowhere near being moneymakers ... yet.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You'll need to be prepared for a long holding period and a hearty helping of risk.

As the proverb goes, talent hits targets that nobody else can hit, but genius hits targets that nobody else can see. If you want your portfolio to outperform, sometimes it's necessary to look for investment opportunities in places outside the mainstream. 

For example, Cybin (CYBN -4.56%) is a biotech that's developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in "magic mushrooms"). Based on a swath of extremely positive coverage in the scientific literature, I'm of the opinion that these psychedelic therapies are going to be a tremendous force for good -- and investor returns -- over the coming years. And Cybin could well be one of the leaders in the psychedelics space, so let's take a look at why it's shaping up to be a brilliant investment.

A neurologist shows a patient an image of his brain scan.

Image source: Getty Images.

Building the right capabilities for success in psychedelics

Cybin has a few technologies that will give it an edge in the market for psychedelics, assuming it eventually gets a drug approved for sale. 

First, there are its drug delivery systems. These include the under-the-tongue dissolving films it developed for its leading program, CYB-001, its clinical-stage psilocybin-based therapy for depression. The company is also planning to use an inhaler system that already has regulatory approval with CYB-004, a preclinical anxiety disorder treatment. 

Both of these delivery modes will give it the ability to finely calibrate dosing for all of its candidates, not to mention reducing the delay between the administration of a therapy and the onset of its effects. And, while it's true that competitors have similar aspirations for granular control of their therapies, most focus on dosing rather than the speed of onset. 

Cybin is also an early mover in using neuroimaging techniques to generate data about how patients' brains behave before, during, and after treatment with psychedelics. That's a key capability, as it'll provide researchers with reams of quantitative data they can use to optimize treatment protocols or even the molecular makeup of the drugs. Furthermore, to my knowledge, no other psychedelics company has opted to make use of similar neuroimaging technology as extensively as Cybin plans to. 

There's more to come

Technology aside, several recent developments suggest that Cybin is preparing for a speedy takeoff

Early in July, the company signed a research and development collaboration with Greenbrook TMS, which will give it access to Greenbrook's network of 129 outpatient mental healthcare facilities. The collaboration could reduce clinical trial costs as it grants Cybin a ready-made patient population from which to recruit participants, making this an important step in the right direction as more of the company's projects move into the clinical stage of development. 

Then there's the uplisting. As of Aug. 5, Cybin's stock is listed on the New York Stock Exchange rather than over the counter. That's a significant milestone, as it means the company has met -- and expects to continue to meet -- a new set of listing requirements. It might not benefit shareholders directly today, but it's a helpful factor that could support higher share prices in the future. 

Finally, if all of what I've said so far isn't convincing, it looks like there are a few analysts on Wall Street that are enthusiastic about this company, too. Five analysts rate the stock as a buy with a consensus price target of $10.50, which is quite a step up from its current price in the $2.30 range. 

Don't forget the risks

As favorable as Cybin's future appears to be, it's important to remember that it's a biotech stock that's deep in uncharted waters. Nobody knows if or when the legality issues surrounding the company's psychedelic molecules will be resolved. 

Likewise, there is no guarantee that its therapies will prove themselves in clinical trials or that its ambitious technologies will live up to their potential. At a minimum, it'll be years before the business has the chance to make any significant revenue through sales of its products, if it ever does. 

In other words, this is a risky stock to buy, and it isn't for everyone. But if you're willing to take a calculated risk and make an investment in a psychedelics developer, Cybin is an excellent option, and people who buy it now could easily see their shares explode in value over time.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Cybin Inc. Stock Quote
Cybin Inc.
CYBN
$0.34 (-4.56%) $0.02
Greenbrook TMS Inc. Stock Quote
Greenbrook TMS Inc.
GBNH
$2.18 (3.80%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.